Biohaven with BHV-7000 underscores unwavering commitment to neurology and to addressing unmet patient needs, by providing innovative therapeutic choices with improved tolerability for epilepsy patients.
BHV-7000, a selective activator of Kv7.2/7.3 potassium channels, presents a promising avenue, navigating the complexities often associated with existing anti-seizure medications by reducing the side effects in the central nervous system.
At the recently concluded American Academy of Neurology Annual Meeting (2024) Biohaven presented abstracts elucidating the characterization of their primary candidate within the Kv7 platform, BHV-7000, as a prospect...